Arecor Therapeutics PLC AREC
LSE · United Kingdom · Health Technology
GBp 71.00-1.50 (-2.07%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) has cleared its final regulatory hurdle, with full MHRA approval secured for its TOPICAL trial across six UK sites. Interim data on its CRS therapy is expected this summer, with US payer research pointing to a big opportunity. Arecor Therapeutics PLC (AIM:AREC) is advancing its lead insulin candidate AT278, which it says outperforms best-in-class rivals for use in insulin pumps. A Phase 2 trial is targeted for the second half of 2026, backed by a partnership with Sequel Med Tech. hVIVO PLC (AIM:HVO) beat EBITDA guidance in 2025 and closed the
Arecor Therapeutics PLC (AIM:AREC) says talks are progressing on a broader partnership for its lead insulin candidate AT278. Releasing its 2025 annual results, the Cambridge-based diabetes biotech said a phase II trial is targeted for the second half of this year. Great Southern Copper PLC (LSE:GSCU, FRA:E9E) has expanded its footprint at the La Colorada prospect in Chile. Five new concessions add 1,000 hectares to what looks like a significant copper-gold target. Powerhouse Energy Group PLC (AIM:PHE, FRA:BT81) has granted a non-exclusive licence of its waste-to-energy technology to Hydrogen U
Arecor Therapeutics PLC's (AIM:AREC) CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company’s second-half performance and its strategic priorities heading into 2026, highlighting progress across its dual focus on diabetes and oral peptide delivery. Howell explained that Arecor is a clinical-stage biopharmaceutical company focused on drug development and enhanced delivery in the cardiometabolic space. The company’s lead asset, AT278, is described as a “new unique best-in-class ultra-concentrated (500 U/mL) and ultra-rapid-acting insulin for the treatment of diabetes,” and is
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.